629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

• Jameel Muzaffar,
• Tae Min Kim,
• Julie Brahmer,
• Dirk G Brockstedt,
• Chia-Chi Lin,
• Michael Chisamore,
• Ki Hyeong Lee,
• Paul D Kassner,
• Nuttapong Ngamphaiboon,
• William Ho,
• Nicole Nasrah,
• Pratibha Desai,
• Yin-Hsun Feng,
• Shang-Yin Wu,
• Rakesh Kumar Goyal

Affiliations

Jameel Muzaffar

6Moffitt Cancer Center, Tampa, FL, USA

Tae Min Kim

1Seoul National University Hospital, Seoul, Republic of Korea

Julie Brahmer

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Dirk G Brockstedt

11RAPT Therapeutics, Inc., South San Francisco, CA, USA

Chia-Chi Lin

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

Michael Chisamore

10Merck and Co., Inc., Rahway, NJ, USA

Ki Hyeong Lee

3Chungbuk National University Hospital, Cheongju, Republic of Korea

Paul D Kassner

11RAPT Therapeutics, Inc., South San Francisco, CA, USA

Nuttapong Ngamphaiboon

2Ramathibodi Hospital, Mahidol Univ., Bangkok, Thailand

William Ho

11RAPT Therapeutics, Inc., South San Francisco, CA, USA

Nicole Nasrah

11RAPT Therapeutics, Inc., South San Francisco, CA, USA

Pratibha Desai

4Comprehensive Hematology Oncology, St. Petersburg, FL, USA

Yin-Hsun Feng

7Chi Mei Medical Center, Tainan, Taiwan

Shang-Yin Wu

8National Cheng Kung University Hospital, Tainan, Taiwan

Rakesh Kumar Goyal

12RAPT Therapeutics, Redwood City, CA, USA